ARMP Logo

Armata Pharmaceuticals, Inc. (ARMP) 

AMEX
Market Cap
$81.41M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
446 of 776
Rank in Industry
234 of 433

Largest Insider Buys in Sector

ARMP Stock Price History Chart

ARMP Stock Performance

About Armata Pharmaceuticals, Inc.

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to …

Insider Activity of Armata Pharmaceuticals, Inc.

Over the last 12 months, insiders at Armata Pharmaceuticals, Inc. have bought $0 and sold $0 worth of Armata Pharmaceuticals, Inc. stock.

On average, over the past 5 years, insiders at Armata Pharmaceuticals, Inc. have bought $30.38M and sold $0 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 5,385,208 shares for transaction amount of $26.93M was made by Innoviva Strategic Opportunities LLC () on 2022‑03‑31.

List of Insider Buy and Sell Transactions, Armata Pharmaceuticals, Inc.

2022-03-31Purchase
5.39M
15.2956%
$5.00$26.93M-26.79%
2022-02-09Purchasedirector
3.61M
12.27%
$5.00$18.07M-21.85%
2021-10-29Purchase
1.21M
5.1858%
$3.30$4M+33.75%
2021-03-17Purchase
4.29M
12.3568%
$3.25$13.93M-25.41%
2021-01-26Purchase
1.87M
8.1521%
$3.25$6.07M+13.46%
2020-03-27Purchase10 percent owner
7.72M
66.226%
$2.87$22.15M+7.19%
2018-03-22Purchasedirector
181,820
1.2965%
$1.10$200,002-16.38%
2018-03-22Purchasedirector
181,820
1.2965%
$1.10$200,002-16.38%
2017-09-19Purchasedirector
105,015
$0$0+11.11%
2017-09-19Purchasedirector
105,015
$0$0+11.11%
2017-06-29Purchasedirector
5,757
$0$0+43.42%
2017-06-29Purchasedirector
5,757
$0$0+43.42%
2016-12-29Sale10 percent owner
42,000
0.3166%
$0.45$18,900-76.14%
2016-12-28Sale10 percent owner
84,620
0.6272%
$0.47$39,771-77.66%
2016-12-27Sale10 percent owner
50,400
0.3723%
$0.51$25,704-79.31%
2016-11-22Purchasedirector
46,666
4.0827%
$7.40$345,328-81.77%
2016-06-21Purchasedirector
15,057
$0$0-70.18%
2016-04-08Purchasedirector
171,298
$0$0-61.41%
2015-10-06Purchasedirector
10,000
0.1764%
$4.39$43,900-31.52%
2015-10-05PurchaseChief Executive Officer
4,200
0.0834%
$4.75$19,950-28.73%

Insider Historical Profitability

<0.0001%
Innoviva Strategic Opportunities LLC
16365969
45.231%
$2.2510<0.0001%
BIOGEN IDEC INC10 percent owner
11704095
32.3469%
$2.25123
ELAN CORP PLC10 percent owner
11626282
32.1318%
$2.2513
Innoviva, Inc.director
10980761
30.3478%
$2.2550+1.43%
KIRK RANDAL J10 percent owner
674169
1.8632%
$2.2513

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Bank of America$2.66M1.76636,638+0.34%+$9,141.66<0.0001
The Vanguard Group$665,494.000.44159,209+9.74%+$59,067.61<0.0001
Bridgeway Capital Management$461,397.000.31110,3820%+$00.01
Edgewood Management$418,000.000.28100,0000%+$0<0.01
Geode Capital Management$417,648.000.2899,888-1.11%-$4,703.81<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.